Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.

被引：0
|
作者：
Vogel, Arndt
Chan, Stephen Lam
Ren, Zhenggang
Bai, Yuxian
Gu, Shanzhi
Lin, Xiaoyan
Chen, Zhendong
Jia, Weidong
Jin, Yongdong
Guo, Yabing
Hu, Xiaohua
Sultanbaev, Alexander Valerievich
Pazgan-Simon, Monika
Pisetska, Margaryta
Nip, Tsz Keung
Zhang, Haisong
Du, Jinghua
Cheng, Ann-Lii
Kaseb, Ahmed Omar
Qin, Shukui
机构：
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[2] Chinese Univ Hong Kong, Hong Kong, Peoples R China
[3] Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Dept Hepat Oncol, Shanghai, Peoples R China
[4] Harbin Med Univ, Dept Gastroenterol, Canc Hosp, Harbin, Peoples R China
[5] Hunan Canc Hosp, Dept Intervent Radiol, Changsha, Peoples R China
[6] Fujian Med Univ, Dept Oncol, Union Hosp, Fuzhou, Peoples R China
[7] Anhui Med Univ, Dept Oncol, Affiliated Hosp 2, Hefei, Peoples R China
[8] Anhui Prov Hosp, Dept Gen Surg, Hefei, Peoples R China
[9] UESTC, Sichuan Canc Hosp & Inst, Dept Med Oncol, Affiliated Canc Hosp,Sch Med, Chengdu, Peoples R China
[10] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Liver Canc Ctr, Guangzhou, Peoples R China
[11] Guangxi Med Univ, Dept Med Oncol, Affiliated Hosp 1, Nanning, Peoples R China
[12] State Autonomous Budgetary Healthcare Inst, Republican Clin Oncol Dispensary, MoH Republ Bashkortostan, Ufa, Russia
[13] Wroclaw Med Univ, Dept Infect Dis & Hepatol, Wroclaw, Poland
[14] Cent Badan Klinicznych P Napora, Wroclaw, Poland
[15] Communal Non Profit Enterprise Reg Ctr Oncol, Dept Liver & Pancreas Gland Oncosurg, Kharkiv, Ukraine
[16] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Jiangsu, Peoples R China
[17] Natl Taiwan Univ Hosp, Taipei, Taiwan
[18] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX, Peoples R China
[19] Canc Ctr Nanjing, Jinling Hosp, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4110
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Overall survival analysis from a randomised phase III trial of axitinib vs sorafenib as first-line therapy in patients with metastatic renal cell carcinoma
    Hutson, T. E.
    Al-Shukri, S.
    Stus, V. P.
    Lipatov, O. N.
    Shparyk, Y.
    Bair, A. H.
    Rosbrook, B.
    Andrews, G. I.
    Vogelzang, N. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S476 - S477
  • [32] Donafenib combined with camrelizumab and transarterial chemoembolization (TACE) as conversion therapy for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm, phase II study.
    Cao, Yajuan
    Zhang, Xuebin
    Yue, Yang
    Peng, Jin
    Li, Binghua
    Shi, Jiong
    Tang, Min
    Chen, Chaobo
    Su, Ke
    Zhang, Laizhu
    Cheng, Chunxiao
    Yu, Decai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Phase II study of first-line trebananib plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Abou-Alfa, Ghassan K.
    Blanc, Jean-Frederic
    Miles, Steven
    Ganten, Tom M.
    Trojan, Jorg
    Cebon, Jonathan S.
    Liem, Andre K. D.
    Lipton, Lara Rachel
    Gupta, Charu
    Wu, Benjamin
    Litten, Jason B.
    Saltz, Leonard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [34] Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Sangro, Bruno
    Chan, Stephen L.
    Kelley, Katie
    Lau, George
    Kudo, Masatoshi
    Sukeepaisarnjaroen, Wattana
    De Toni, Enrico
    Furuse, Junji
    Kang, Yoon-Koo
    Galle, Peter R.
    Rimassa, Lorenza
    Heurgue, Alexandra
    Tam, Vincent C.
    Dao, Tu Van
    Thungappa, Satheesh Chiradoni
    Breder, Valeriy
    Ostapenko, Yuriy
    Reig, Maria
    Makowsky, Mallory
    Gupta, Charu
    Negro, Alejandra
    Abou-Alfa, Ghassan
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 69 - 70
  • [35] Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) therapy for unresectable hepatocellular carcinoma (uHCC): CheckMate 9DW expanded analyses.
    Kudo, Masatoshi
    Yau, Thomas
    Decaens, Thomas
    Sangro, Bruno
    Qin, Shukui
    Da Fonseca, Leonardo
    Karachiwala, Hatim
    Park, Joong-Won
    Gane, Edward
    Pinter, Matthias
    Tai, David
    Santoro, Armando
    Pizarro, Gonzalo
    Chiu, Chang-Fang
    Schenker, Michael
    He, Aiwu Ruth
    Hu, Nan
    Jimenez Exposito, Maria Jesus
    Stromko, Caitlyn
    Galle, Peter Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 520 - 520
  • [36] Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
    Cheng, Ann-Lii
    Kang, Yoon-Koo
    He, Aiwu Ruth
    Lim, Ho Yeong
    Ryoo, Baek-Yeol
    Hung, Chao-Hung
    Sheen, I-Shyan
    Izumi, Namiki
    Austin, TaShara
    Wang, Qiang
    Greenberg, Jonathan
    Shiratori, Shinichi
    Beckman, Robert A.
    Kudo, Masatoshi
    JOURNAL OF HEPATOLOGY, 2015, 63 (04) : 896 - 904
  • [37] Independent imaging review (IIR) results in a phase 3 trial of lenvatinib (LEN) versus sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC).
    Lencioni, Riccardo
    Kudo, Masatoshi
    Finn, Richard S.
    Qin, Shukui
    Han, Kwang-Hyub
    Ikeda, Kenji
    Cheng, Ann-Lii
    Piscaglia, Fabio
    Han, Guohong
    Ikeda, Masafumi
    Simon, Krzysztof
    Komov, Dmitry
    OuYang, Xuenong
    Evans, T. R. Jeffry
    Sung, Max W.
    Binder, Terri A.
    Damon, Andrew
    Kraljevic, Silvija
    Ren, Min
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [38] Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Peng, Ye
    Zeng, Xiaohui
    Peng, Liubao
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Wang, Liting
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [39] Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
    Abou-Alfa, Ghassan K.
    Chan, Stephen Lam
    Kudo, Masatoshi
    Lau, George
    Kelley, Robin Kate
    Furuse, Junji
    Sukeepaisarnjaroen, Wattana
    Kang, Yoon-Koo
    Dao, Tu V.
    De Toni, Enrico N.
    Rimassa, Lorenza
    Breder, Valeriy Vladimirovich
    Vasilyev, Alexander
    Heurgue, Alexandra
    Tam, Vincent
    Mody, Kabir
    Thungappa, Satheesh Chiradoni
    He, Philip
    Negro, Alejandra
    Sangro, Bruno
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [40] Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma
    Liao, Weiting
    Xu, Huiqiong
    Hutton, David
    Wu, Qiuji
    Yang, Yang
    Feng, Mingyang
    Lei, Wanting
    Bai, Liangliang
    Li, Junying
    Li, Qiu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
12345